Actually, most consent forms for placebo-controlled RCTs which I have seen do not use the expression, “it is not known.”
Many of them provide information based upon which prospective subjects could make either of two seemingly inconsistent inferences: 1) The consent form usually refers to preliminary evidence that the active drug is effective and labels the placebo as “an inert substance.” In presenting the risks of placebo, it may also refer to the perils of withholding active therapy. F
rom such information the prospective subject could reasonably infer that the investigator already believes that the active drug is more likely than not to prove superior to placebo. 2) Institutional Review Boards (IRBs) generally constrain investigators from making clear statements that the investigational drug is likely to be effective, reasoning that if this were already known, it would invalidate the null hypothesis used to justify the RCT. Following this reasoning, grounded in the concept of theoretical equipoise, it is considered unethical to tell subjects that a new drug is likely to be effective until the RCT demonstrates that it is. IRBs generally require that subjects be informed that “the purpose of this study is to
determine whether the drug is effective.” Since in order to do this it will be compared with placebo, the subject could infer that “it is not known whether the new drug is better or worse than placebo.”
Google Scholar